MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Catalyst Pharmaceuticals DSO Ratio 2011-2026 | CPRX
Annual DSO Ratio Catalyst Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 44.2 | 29.3 | 14.5 | 16.3 | 25.3 | 37.6 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 44.2 | 14.5 | 27.9 |
Quarterly DSO Ratio Catalyst Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53 | 42.7 | 44.1 | - | 40.9 | 43.8 | 52.8 | - | 40.4 | 34.9 | 23.4 | - | 15.1 | 17.3 | 18.2 | - | 16.4 | 14.9 | 17.5 | - | 18.6 | 18.4 | 25.9 | 31.9 | 31.1 | 33.3 | 38.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 53 | 14.9 | 30.6 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
Adagene
ADAG
|
53.8 | $ 2.8 | -3.69 % | $ 158 M |  China |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
114 | $ 80.89 | -1.35 % | $ 1.56 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Amgen
AMGN
|
76.7 | $ 341.41 | -0.45 % | $ 183 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Aytu BioScience
AYTU
|
150 | $ 2.68 | 3.88 % | $ 16.8 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.23 | -1.01 % | $ 7.77 B |  Australia |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | USA |
 |
Biogen
BIIB
|
57.9 | $ 177.21 | 0.61 % | $ 25.8 B | USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 224.26 | 0.14 % | $ 5 B |  Danmark |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 68.78 | -0.5 % | $ 9.2 B | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
CASI Pharmaceuticals
CASI
|
87.4 | $ 1.01 | 1.6 % | $ 137 M | USA |
 |
Catalyst Biosciences
CBIO
|
3.24 | $ 9.79 | -3.55 % | $ 644 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | Britain |
 |
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 4.0 | -3.61 % | $ 8.7 B |  Israel |
 |
Amneal Pharmaceuticals
AMRX
|
55.7 | $ 14.0 | -0.78 % | $ 4.33 B | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Cerus Corporation
CERS
|
59.2 | $ 2.28 | -1.94 % | $ 421 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Baudax Bio
BXRX
|
126 | - | 0.59 % | $ 63 K | USA |